Erythropoietin for newborn brain injury in low-resource settings
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This Phase 3 trial studies whether erythropoietin (a medicine related to red-blood-cell growth) can improve outcomes for newborns with moderate to severe brain injury after birth. The study focuses on babies born in low- and middle-income countries and aims to reduce harm from this early brain condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Baby was born at 36 weeks or later, and weighed at least 1.8 kg at birth
- Baby shows signs of needing extra help right after birth or has abnormal blood tests early on (within the first hour)
- Baby is diagnosed with moderate or severe neonatal encephalopathy within 1 to 6 hours after birth
- Baby is not in immediate danger of dying at the time the study would start
- Baby can be brought back for follow-up at about 18 months (or families are likely to return)
- Baby was not given whole-body cooling (induced hypothermia) for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether cooling a newborn’s body can help babies with mild brain injury after a difficult birth. It aims to see if cooling improves brain-related outcomes compared with standard care.
This study tests whether a medicine called erythropoietin can help newborns with a brain injury from lack of oxygen (HIE). It is for babies less than 1 month old and aims to see if the treatment improves their recovery.
This early-phase study tests whether using a baby’s own cord blood stem cells is safe and feasible for newborns with brain injury from lack of oxygen around birth. It may help researchers find new ways to treat hypoxic-ischemic encephalopathy (brain injury due to oxygen deprivation) in addition to standard care like cooling.
This trial is for newborn babies who had an oxygen shortage around birth and now have severe brain injury. It aims to test approaches that may help improve outcomes after this kind of early-life brain damage.
This study looks at a special blood marker in full-term newborns who had brain injury from lack of oxygen during birth. It aims to help doctors better understand and treat this condition.
This trial is testing a treatment for newborns who had low oxygen around birth, leading to brain injury. It may help babies who did not get certain medicines before birth.
Hear when a new Encephalopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.